Health Care·NASDAQ·All covered stocks

BridgeBio Pharma Inc. (NASDAQ: BBIO) Stock News & Analysis

BridgeBio Pharma Inc. (NASDAQ: BBIO) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 4 articles on BBIO since April 30, 2026, most recently "BridgeBio (NASDAQ:BBIO) Q2 Revenue More Than Doubles to $243.7M as Attruby Sales Hit $222.4M" on Tuesday, August 11, 2026. Coverage to date spans Earnings Report and Health Care, tracking BBIO's earnings, analyst activity, and material corporate events. New coverage is added each trading day.

Price

$76.08

Today

+1.77%

Mkt Cap

$14.9B

52W High

$93.42

52W Low

$48.78

Data via Finnhub · refreshes hourly · not financial advice

BBIO Coverage -- 4 Articles

Earnings Report·Tuesday, August 11, 2026

BridgeBio (NASDAQ:BBIO) Q2 Revenue More Than Doubles to $243.7M as Attruby Sales Hit $222.4M

Attruby drove a 120.4% revenue jump at BridgeBio, but a $-0.78 EPS miss vs. the $-0.60 estimate shows the cost of funding three imminent drug launches.

5 min readRead article

Important Legal Disclaimer

This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.

Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.

Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.